|
|
1) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.
Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP.
Rheumatology (Oxford). 2010 Feb;49(2):271-80. Epub 2009 May 15.
http://rheumatology.oxfordjournals.org/cgi/reprint/49/2/271
2) Predictors of major infections in systemic lupus erythematosus .
Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C.
Arthritis Res Ther. 2009;11(4):R109. Epub 2009 Jul 15.
http://arthritis-research.com/content/11/4/R109
3) Antiphospholipid antibodies and renal involvement.
Gigante A, Gasperini ML, Cianci R, Barbano B, Giannakakis K, Di Donato D, Fuiano G, Amoroso A.
Am J Nephrol. 2009;30(5):405-12. Epub 2009 Aug 28.
http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=000235941
4) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis.
Visser K, et al. Ann Rheum Dis 2009.
http://ard.bmj.com/content/68/7/1086.full.pdf+html
5) Antiphospholipid syndrome.
Espinosa G, Cervera R. Art Res Ther 2008.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656223/pdf/ar2536.pdf
6) Primary Sjögren Syndrome in Spain. Clinical and immunological expression in 1010 patients.
Ramos-Casals M, et al. Medicine (Baltimore) 2008.
http://www.fesemi.org/grupos/otros/publicaciones/sjogren_medicine.pdf
7) A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies.
Ruiz-Irastorza G, et al. Art Rheum 2007.
http://www3.interscience.wiley.com/cgi-bin/fulltext/117347083/PDFSTART?CRETRY=1&SRETRY=0
|
|
